Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...
WASHINGTON — The U.S. will likely begin distributing a third vaccine against COVID-19 in the next week, and health officials are girding for questions about which one is best. The Johnson & Johnson ...
Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck & Co. and Moderna to complete an unchanged top three from the last edition of the survey. But, while the rankings held ...
1mon
Moderna Vaccine
Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.
RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...
Stocktwits on MSN
NVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna again
Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results